NA
JAZZ icon

NewEdge Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

NewEdge Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373K Buy
1,975
+1,126
+133% +$197K ﹤0.01% 2190
2025
Q4 		$144K Sell
849
-51
-6% -$7.82K ﹤0.01% 2671
2025
Q3 		$119K Sell
900
-67
-7% -$8.04K ﹤0.01% 2548
2025
Q2 		$103K Sell
967
-49
-5% -$5.32K ﹤0.01% 2415
2025
Q1 		$126K Sell
1,016
-21
-2% -$2.74K ﹤0.01% 2220
2024
Q4 		$128K Sell
1,037
-230
-18% -$27.1K ﹤0.01% 2211
2024
Q3 		$141K Sell
1,267
-70
-5% -$7.67K ﹤0.01% 2087
2024
Q2 		$143K Sell
1,337
-194
-13% -$21.3K ﹤0.01% 2013
2024
Q1 		$184K Buy
1,531
+392
+34% +$48K ﹤0.01% 1868
2023
Q4 		$140K Sell
1,139
-63
-5% -$7.86K ﹤0.01% 1828
2023
Q3 		$156K Sell
1,202
-77
-6% -$10.3K ﹤0.01% 1703
2023
Q2 		$159K Buy
1,279
+144
+13% +$19.4K ﹤0.01% 1710
2023
Q1 		$166K Sell
1,135
-273
-19% -$40.4K ﹤0.01% 1601
2022
Q4 		$6.59K Buy
+1,408
New +$206K ﹤0.01% 2502
2022
Q1 		– Sell
-3,128
Closed -$399K – 1392
2021
Q4 		$399K Sell
3,128
-167
-5% -$21.9K 0.01% 1185
2021
Q3 		$429K Buy
3,295
+1,664
+102% +$251K 0.01% 790
2021
Q2 		$290K Buy
+1,631
New +$283K 0.01% 919
2017
Q3 		– Sell
-26
Closed -$3.98K – 748
2017
Q2 		$3.98K Buy
+26
New +$3.98K ﹤0.01% 1184

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NewEdge Advisors's JAZZ Position: Q1 2026 in Review

NewEdge Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 133% in Q1 2026, buying an estimated $197K and bringing the position to 1,975 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

NewEdge Advisors first reported a position in JAZZ in Q2 2017 and has held it in 18 quarters since. The position peaked at $429K in Q3 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • NewEdge Advisors held 1,975 shares of Jazz Pharmaceuticals worth $373K as of Q1 2026.
  • NewEdge Advisors bought 1,126 Jazz Pharmaceuticals shares in Q1 2026, an estimated $197K.
  • Jazz Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2190 holding.
  • NewEdge Advisors first reported a position in Jazz Pharmaceuticals in Q2 2017 and has held it in 18 quarters since.
  • NewEdge Advisors's Jazz Pharmaceuticals position peaked at $429K in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.